Beam CEO exercises options, sells 50K shares
Beam Therapeutics Inc. CEO John M. Evans reported a series of option exercises and related share sales in Beam Therapeutics common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Beam Therapeutics Inc. CEO John M. Evans reported a series of option exercises and related share sales in Beam Therapeutics common stock. He exercised options covering 50,000 shares at strike prices of $1.03 and $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices in the mid-$30s.
The filing shows these trades were executed pursuant to a Rule 10b5-1 trading plan. Following the transactions, Evans continues to hold over 1.0 million shares of Beam Therapeutics common stock directly, and 103,000 shares indirectly through the John M. Evans, III 2018 Irrevocable Trust.
Insider Trade Summary 10b5-1
Exercise and Sale: 50,000 shares ($1.70M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Evans John M.
Role
CEO
Sold
50,000 shs ($1.75M)
Approx. gross sale proceeds
$1.75M
Approx. exercise cost
$45K
Approx. pre-tax spread
$1.70M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $1.03 | $26K |
| Sale | Common Stock | 23,100 | $34.2633 | $791K |
| Sale | Common Stock | 1,900 | $34.8437 | $66K |
| Exercise | Stock Option (Right to Buy) | 18,663 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 6,337 | $0.00 | $0.00 |
| Exercise | Common Stock | 18,663 | $0.67 | $13K |
| Exercise | Common Stock | 6,337 | $1.03 | $7K |
| Sale | Common Stock | 13,421 | $35.1336 | $472K |
| Sale | Common Stock | 11,579 | $35.9119 | $416K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 205,813 contracts (Direct);
Common Stock — 1,047,205 shares (Direct);
Common Stock — 103,000 shares (Indirect, By John M. Evans, III 2018 Irrevocable Trust)
Footnotes (7)
- F1. The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
- F7. On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Key Figures
Shares sold: 50,000 shares
Sale prices: $34–$36 per share (weighted averages)
Options exercised: 50,000 shares
+5 more
8 metrics
Shares sold
50,000 shares
Total open-market sales in this Form 4
Sale prices
$34–$36 per share (weighted averages)
Ranges from multiple sale transactions
Options exercised
50,000 shares
Total shares from option exercises (code M)
Strike price 1
$0.67 per share
Stock option exercise price for 18,663 shares
Strike price 2
$1.03 per share
Stock option exercise price including 25,000-share grant
Direct holdings after trades
1,047,205 shares
Total common stock directly held after reported transactions
Indirect trust holdings
103,000 shares
Common stock held by John M. Evans, III 2018 Irrevocable Trust
Option grant vesting
99,336 shares
Portion of 2018 option vesting after performance milestone
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), development milestone, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
development milestone technical
"vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications."
performance condition financial
"the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting..."
Irrevocable Trust financial
"nature_of_ownership": "By John M. Evans, III 2018 Irrevocable Trust""
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BEAM CEO John M. Evans report on this Form 4?
John M. Evans reported exercising options for 50,000 Beam Therapeutics shares and selling 50,000 shares in open-market trades. The sales occurred at weighted average prices in the mid-$30s, paired with low-cost option exercises at $1.03 and $0.67 per share.
What stock options did the BEAM CEO exercise in this Form 4 filing?
Evans exercised stock options covering 50,000 Beam Therapeutics shares at low strike prices. The filing shows option exercises for 18,663 shares at $0.67 and 31,337 shares at $1.03 per share, converting previously granted options into common stock before the related sales.
What do the weighted average prices mean in the BEAM Form 4 footnotes?
Weighted average prices represent the average sale price across multiple trades executed within a price range. The Form 4 explains that Beam Therapeutics shares were sold in numerous transactions at different prices, and Evans offers to provide exact share counts at each price upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates